大麻使用不影响全膝关节置换术后的结局
本研究回顾性纳入71例自报使用大麻并接受初次单侧全膝关节置换术(TKA)且随访至少1年的患者,按年龄、体质指数、性别、吸烟状态和保险类型匹配未使用大麻的对照。结果显示两组在住院时长、住院期间吗啡当量、术后活动度、膝关节社会评分(KSS)、Veterans RAND-12评分、再入院和再手术方面均无显著差异。作者认为大麻使用似乎不影响初次TKA的短期结局,但需进一步研究以确定大麻作为多模式疼痛管理组成部分的疗效和安全性。
要点
- 大麻使用组与未使用组在住院时长、住院吗啡当量和术后活动度上无显著差异。
- 两组在随访KSS、KSS总变化及Veterans RAND-12心理和躯体评分上均无显著差异。
- 再入院和再手术率两组无显著差异,但作者认为需进一步研究才能认可大麻用于TKA后疼痛管理。
核心结论
- 大麻使用似乎不影响初次全膝关节置换术患者的短期结局( adverse 或 beneficial 均未见)。
- 作者认为在骨科医生认可大麻作为全膝关节置换术后多模式疼痛管理组成部分之前,需进一步研究其疗效和安全性。
研究设计与样本
- 回顾性研究,研究期间为2014年1月至2018年2月,单中心。
- 纳入71例自报使用大麻并接受初次单侧全膝关节置换术且随访至少1年的患者;排除有阿片类药物使用史、酒精滥用、吸烟或非法药物使用史的患者。
- 按年龄、体质指数、性别、吸烟状态和保险类型(社会经济地位替代指标)匹配未报告大麻使用的单侧全膝关节置换术患者作为对照。
主要发现
- 住院时长:使用组46.9小时±15.7 vs 未使用组49.3小时±20.4(P=0.464)。
- 住院期间总吗啡当量:使用组137±104 mg vs 未使用组146±117 mg(P=0.634)。
- 术后活动度:使用组128.4°±10.4° vs 未使用组126.9°±7.5°(P=0.346)。
- 随访KSS:使用组180.1±24.9 vs 未使用组172.0±33.9(P=0.106);KSS总变化:使用组61.7±32.8 vs 未使用组62.7±30.7(P=0.852)。
- Veterans RAND-12心理成分评分:使用组54.8±9.3 vs 未使用组55.9±8.79(P=0.472);躯体成分评分:使用组48.3±9.9 vs 未使用组45.8±10.1(P=0.145);再入院:使用组5例 vs 未使用组4例(P=0.730);再手术:使用组5例 vs 未使用组2例(P=0.238)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 作者结论指出需进一步研究以确定大麻作为全膝关节置换术后多模式疼痛管理组成部分的疗效和安全性,之后骨科医生才能认可。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The self-reported use of cannabis has increased since its recent legalization in several states. The primary purpose of this study is to report total knee arthroplasty (TKA) outcomes in patients using cannabis. METHODS: Seventy-one patients who underwent a primary unilateral TKA with minimum 1-year follow-up, who self-reported cannabis use, were retrospectively reviewed. The study period was from January 2014 to February 2018 at a single institution. Patients with a history of opioid consumption, alcohol abuse, tobacco, or illicit drug use were excluded. A matched control was conducted based on age, body mass index, gender, smoking status, and insurance type (surrogate of socioeconomic status) in patients with a unilateral TKA who did not report cannabis use. Outcome measures included Knee Society Scores (KSS), range of motion, Veterans RAND-12 mental and physical component scores. No preoperative differences were noted with these measures. Postoperative complications were recorded and reported. RESULTS: No difference in length of stay was noted between the users (46.9 hours ± 15.7) and nonusers (49.3 hours ± 20.4) (P = .464). In-hospital total morphine equivalents did not differ between the 2 groups (user = 137 ± 104 mg, nonuser = 146 ± 117 mg, P = .634). Postoperative range of motion did not differ between users (128.4° ± 10.4°) and nonusers (126.9° ± 7.5°) (P = .346). No mean differences in follow-up KSS (user = 180.1 ± 24.9, nonuser = 172.0 ± 33.9, P = .106) or total change (user = 61.7 ± 32.8, nonuser = 62.7 ± 30.7, P = .852) in KSS were noted. Likewise, no significant mean differences in Veterans RAND-12 (mental component scores: user = 54.8 ± 9.3, nonuser = 55.9 ± 8.79, P = .472; physical component scores: user = 48.3 ± 9.9, nonuser = 45.8 ± 10.1, P = .145) scores were demonstrated. There were no differences in readmissions (user = 5, nonuser = 4, P = .730) or reoperations (user = 5, nonuser = 2, P = .238). CONCLUSION: Cannabis use does not appear to influence (adverse or beneficial) short-term outcomes in patients undergoing a primary TKA. Further studies are warranted to determine the efficacy and safety of cannabis as a constituent of multimodal pain management following TKA before endorsements can be made by orthopedic surgeons.
引用
- Jennings JM, Angerame MR, Eschen CL, et al. Cannabis Use Does Not Affect Outcomes After Total Knee Arthroplasty. J Arthroplasty. 2019. PMID: 31072746. doi:10.1016/j.arth.2019.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。